OmiSure: Tata Medical and Diagnostics Develops Kit To Detect Omicron COVID-19 Variant in RT-PCR Tests

Mumbai, January 4: The Tata Medical and Diagnostics has developed a kit 'OmiSure' that can detect the Omicron variant of SARS-CoV2 in nasopharyngeal/oropharyngeal specimens during the RT-PCR tests, a senior company executive said on Tuesday.

The test kit is compatible with all standard Real-Time PCR Machines. The first target is based on S-gene dropout or S-gene target failure (SGTF), and the second target is based on S-gene mutation amplification (SGMA), said Ravi Vasanthapuram, the head of the research and development of TATA MD. Also Read | Saffron Scarf vs Hijab Row: Balagadi First Grade College Management To Hold Parents' Meeting in Karnataka.

“This kit can detect the Omicron variant as well as other variants of SARS-CoV2 reported so far. Currently, Omicron patients are detected only after genome sequencing. But this test can help eliminate that step and detection can be done during the testing,” he told PTI. Also Read | Delhi Reports 5,481 Fresh COVID-19 Cases, 3 Deaths in Past 24 Hours; Sources Say 'Onset of Third Wave'.

According to the Indian Medical Research Council, it approved OmiSure on December 30. The kit has been developed for “direct and very specific detection” of the new variant of SARS-CoV2, he stressed. Also Read | Delhi Reports 5,481 Fresh COVID-19 Cases, 3 Deaths in Past 24 Hours; Sources Say 'Onset of Third Wave'.

Cases have been surging in India as well as the globe after the new variant was classified as 'Variant of Concern' by the World Health Organisation in the last week of November.

Vasanthapuram said the test run time of this kit is 85 minutes. The result turnaround time, including sample collection and RNA extraction, is 130 minutes.

Currently, all tests across the globe employ either SGTF or SGMA, but this unique test design combines both, he said. Therefore, it has two checks in place for Omicron detection without compromising the ability to detect other SARS-CoV-2 variants, Vasanthapuram added.

When asked about the commercialisation, Vasanthapuram said the company has applied for a license with the Central Drugs Standard Control Organisation (CDSCO).

He said once the license is approved by the CDSCO, the kit will be manufactured by TATA MD at its Sriperumbudur facility in Tamil Nadu. It currently has the capacity of manufacturing 2,00,000 kits daily but plans are on to ramp up the capacity to 5,00,000 to 10,00,000 by the third week of January.

“The kit will be manufactured for both domestic and international markets,” he added. Vasanthapuram declined to comment on the price of the kit but said it would be competitive and mostly cost around what the existing RT-PCR tests cost. The company also applied for a patent for this kit on December 23. Mumbai's COVID-19 graph has been rising steadily.

The Maharashtra capital on Tuesday reported 10,860 cases, up 34.37 per cent from a day before, and 2 deaths, taking infection tally to 8,18,462 and toll to 16,381, according to the civic body. The tally of Omicron cases in Mumbai stood at 368 as on Monday, the Maharashtra government's health department had said.

(This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)